

Government of Western Australia North Metropolitan Health Service Women and Newborn Health Service



NEONATAL MEDICATION GUIDELINE					
Calcitriol					
Scope (Staff):	Nursing, Medical and Pharmacy Staff				
Scope (Area):	KEMH NICU, PCH NICU, NETS WA				
This document should be read in conjunction with the Disclaimer.					

Quick Links										
Dose	Preparation & Administration	Side Effects & <u>Interactions</u>	Monitoring							
Restrictions										
Formulary: Restricted										
SAS Category A (injection requires approval by TGA)										
Description										
Activated Vitamin D3 - increases calcium and phosphorous absorption. Activates the parathyroid hormone to increase bone resorption, maintaining calcium and phosphorous levels.										
Presentation										
Oral Solution: 1 microgram / mL Ampoule: 1 microgram / mL (SAS)										
Storage										
Store at room temperature, below 25°C. Protect from light.										
Dose										
Hypocalcaemia, Hypoparathyroidism, Neonatal Rickets										
Oral:										
Initially 0.25 microgram to 1 microgram ONCE a day.										
Increase by 0.25microgram every 4 weeks according to Calcium levels.										

Adjust dose to maintain serum calcium in the lower range.

Intravenous:

Initially 0.25 microgram ONCE daily.

Switch to oral when tolerating oral feeds.

Dose Adjustment

Renal Impairment: Not documented

Hepatic Impairment: Not documented

Administration

<u>Oral</u>

Can be administered any time in regard to feeds.

Intravenous

Push undiluted over at least 15 second.

Discard any unused portion.

Compatible Fluids

Glucose 5%, sodium chloride 0.9%

Y-Site Compatibility

Refer to KEMH Neonatal Medication Guideline: Y-Site IV Compatibility in Neonates

Side Effects

Adverse effects are associated with hypercalcaemia

Common: weakness, headache, nausea, vomiting, dry mouth, constipation, myalgia, bone pain, metallic taste, anorexia, abdominal pain, polyuria, polydipsia, anorexia, weight loss, nocturia

Serious: conjunctivitis (calcific), pancreatitis, photophobia, rhinorrhea, pruritus, hyperthermia, elevated blood urea nitrogen (BUN), albuminuria, hypercholesterolemia, elevated SGOT (AST) and SGPT (ALT), ectopic calcification, nephrocalcinosis, hypertension, cardiac arrhythmias, dystrophy, sensory disturbances, dehydration, apathy, arrested growth, urinary tract infections.

Interactions

Calcitriol can cause hypercalcaemia; calcium supplements or administration with other drugs that can cause hypercalcaemia may increase this risk; monitor calcium concentration.

Monitoring

Serum calcium and phosphorous, serum alkaline phosphatase, creatinine, urinary calcium

Comments

Calcitriol adsorbs to PVC. If being given, PVC lines can be used however calcium and phosphate levels should be monitored and dose adjusted accordingly.

Consider the vitamin D content of feeds and other medications when administering calcitriol.

Intravenous calcitriol requires an SAS form to be completed prior to use.

Related Policies, Procedures & Guidelines

WNHS Pharmaceutical and Medicines Management Guidelines:

Medication Administration

References

Australian Medicines Handbook. Calcitriol. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Sep 28]; Available from: https://amhonline.amh.net.au/

Truven Health Analytics. Calcitriol. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2021 [cited 2021 Sep 28]. Available from: <u>https://neofax.micromedexsolutions.com/</u>

Government of South Australia: SA Health [Internet]. South Australian Neonatal Medication Guidelines;2017 [cited 2021 Sep 28]. Available from: <u>Neonatal Medication Guidelines | SA Health</u>

Takemoto CK, Hodding JH, Kraus DM. Calcitriol (Systemic). In: Pediatric & neonatal dosage handbook with international trade names index: a universal resource for clinicians treating pediatric and neonatal patients. 27th ed. Hudson (Ohio): Lexicomp; 2020. P298-299.

Keywords	Calcitriol, hypocalcaemia, rickets, hypoparathyroidism, activated vitamin d3							
Document Owner:	Head of Department - Neonatology							
Author/ Reviewer	KEMH & PCH Pharmacy/Neonatology Directorate							
Version Info:	V4 (2021): Added Intravenous route dosing, preparation and administration							
Date First Issued:	AUG 2013	Last Reviewed:	28/09/2021		Review Date:	28/09/2024		
Endorsed by:	Neonatal Directorate Management Group				Date:	25/01/2022		
NSQHS Standards Applicable:	Std 1: Clinical Governance			Std 5: Comprehensive Care				
	Std 2: Partnering with Consumers			Std 6: Communicating for Safety				
	Std 3: Preventing and Controlling Healthcare Associated Infection			Std 7: Blood Management				
	Std 4: Medication Safety			Std 8: Recognising and Responding to Acute Deterioration				
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.								

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2020

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.